Welcome to our dedicated page for ELI LILLY & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ELI LILLY & Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ELI LILLY & Co's regulatory disclosures and financial reporting.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported open‑market sales totaling 300,000 shares of common stock on 11/03/2025.
The trades were executed in multiple tranches at weighted average prices with reported ranges from $877.00 to $901.295 per share, as detailed in footnotes. Following these transactions, the reporting person beneficially owned 93,931,978 shares directly.
Lilly Endowment Inc. filed a Form 144 notice to sell up to 220,000 shares of Eli Lilly and Company (LLY) common stock, reflecting an aggregate market value of $197,236,600. The filing lists J.P. Morgan Securities LLC as broker and an approximate sale date of 11/04/2025.
Shares outstanding were 945,383,757. The Endowment reports prior sales in the last three months, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 300,000 shares on 11/03/2025 for $266,648,940. The securities trace back to a historical gift acquisition from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Lilly Endowment Inc. filed a Form 144 notice to sell 300,000 shares of Eli Lilly and Company common stock. The filing lists an aggregate market value of $258,858,000, with Fidelity Capital Markets as broker and an approximate sale date of 11/03/2025. The shares are listed on NYSE and NASDAQ.
Shares outstanding were 945,383,757; this is a baseline figure, not the amount being offered. In the past three months, the seller reported multiple open-market sales, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 301,342 shares on 10/31/2025 for $260,164,971.74.
Lilly Endowment, Inc. filed Amendment No. 43 to Schedule 13G reporting beneficial ownership of 95,492,993 shares of Eli Lilly (LLY) common stock, representing 10.1% of the class. The ownership is reported as of September 30, 2025, and the percentage is based on 946,456,759 shares outstanding as of August 4, 2025 per the issuer’s Form 10‑Q.
The Endowment has sole voting power and sole dispositive power over 95,492,993 shares, with no shared voting or dispositive power. The filer is an Indiana not‑for‑profit organization and private foundation.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of Eli Lilly (LLY) common stock. As of 09/30/2025, Vanguard reported 80,952,595 shares, representing 8.55% of the class. Vanguard is identified as an investment adviser and certified the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing details 0 shares with sole voting power and 4,843,238 shares with shared voting power. Vanguard reported 73,223,987 shares with sole dispositive power and 7,728,608 shares with shared dispositive power. The filing also notes that Vanguard’s clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
Eli Lilly (LLY) reported sharply higher Q3 results. Revenue rose to $17,600.8 million from $11,439.1 million a year ago, driven by cardiometabolic medicines. Net income increased to $5,582.5 million from $970.3 million, with diluted EPS of $6.21 versus $1.07.
Growth was led by Mounjaro ($6,515.1 million total) and Zepbound ($3,588.1 million), lifting total cardiometabolic health revenue to $13,177.9 million. Oncology contributed $2,407.6 million, and immunology $1,362.4 million. Operating cash flow for the nine months reached $13,588.4 million. Cash and equivalents were $9,791.9 million, while long‑term debt was $40,873.6 million. The company recognized $655.7 million of acquired IPR&D and $364.9 million of special charges in the quarter.
Lilly completed the Verve Therapeutics acquisition for $549.4 million net of cash, with a contingent value right of up to $300.0 million. Pre‑launch inventories were $952.3 million, primarily for orforglipron. As of September 30, $12.40 billion remained under the $15.00 billion share repurchase authorization. Shares outstanding were 945,383,757 as of October 27, 2025.
Eli Lilly and Company furnished an 8-K under Item 2.02 to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into Item 2.02.
The information in Item 2.02 is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes Exhibit 104 for the cover page Inline XBRL. The document identifies Lilly’s listed securities, including common stock (LLY) on the NYSE.
Eli Lilly (LLY) reported an insider transaction by a director on 10/20/2025. The filing shows an acquisition of 6.129 shares of common stock at $808.96 per share, bringing the director’s direct beneficial ownership to 2,728.14 shares.
According to the footnote, the acquired amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person’s separation from service.
Eli Lilly (LLY) director reported a routine equity accrual. On 10/20/2025, the director acquired 18.336 shares of common stock at $808.96 per share, recorded as an “A” (acquisition). Following this transaction, the director beneficially owns 16,474.296 shares, held directly.
The filing notes these shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after the director’s separation from service.